My Philosophy


A patient recently asked me, “What is your philosophy on patient care?”

The first thing that came to mind was this: My focus is to provide personalized compassionate care.

What does that mean? It means that I believe strongly in getting to know my patients. We don’t run a factory. We don’t run patients through our office on an assembly line without getting to know who they are.

Instead, we sit down and talk to our patients, no matter how much time it takes. I want to hear your story. I want to know what’s happening withyour vision and how it’s affecting your life.

Loss of vision is an extremely stressful and frightening proposition. I understand that. And I want to help.

The good news is that, most of the time I can help. The last 10 years have seen an explosion in new treatments and medications for various retinal diseases, from macular degeneration to diabetic retinopathy. If we can’t “cure” your disease, we can usually slow it down and improve the quality of your life.

And that’s wonderfully exciting. For me and for my patients.

What else do you need to know about me? Well, you should know that I believe in evidence-based medicine. That means I’m not interested in experimenting with unproven drugs or treatments.

What I am interested in is providing my patients with the best in proven, cutting-edge treatments for their particular disease. We use state-of-the-art equipment, and we stay on top of the research so that our patients can benefit from the latest findings.

Take Avastin and Lucentis, two medications that, just in the last few years, were discovered to be effective in the treatment of age-related macular degeneration (AMD). In its advanced stages, AMD spurs the growth of abnormal blood vessels, which can leak fluid and blood into the eye, threatening your vision. Both Avastin and Lucentis halt the growth of these abnormal blood vessels.

In fact, a recent NIH-funded study (known as the CATT study) found that two years after starting monthly treatments with Avastin or Lucentis for macular degeneration, two-thirds of patients had driving vision (20/40 or better), compared with just 15 percent of patients before the advent of these drugs. Recent clinical trials have also demonstrated a strong treatment benefit when Lucentis is used to treat macular edema from diabetes or retinal vein occlusion.

Getting to know our patients. Helping them understand the nature of their condition. Being able to restore their vision. That’s personalized compassionate care. It’s simple. And it’s at the heart of what we do.

***This post is for information purposes only. This posting does not offer medical advice, so nothing in it should be construed as medical advice. The information on this blog/post is only offered for informational purposes. You shouldn’t act or rely on anything in this blog or posting or use it as a substitute for medical advice from a licensed professional. The content of this posting may quickly become outdated, especially due to the nature of the topics covered, which are constantly evolving. The materials and information on this posting/blog are not guaranteed to be correct, complete, or timely. Nothing in this posting/blog and nothing you or I do creates a doctor-patient relationship between you and the blog; between you and me; or between you and Joseph J. Timmes, Jr., M.D., F.A.C.S. or Even if you try to contact me through the blog or post a comment on the blog you are still not creating a doctor-patient relationship. Although, I am a doctor, I’m not YOUR doctor until and unless there is a written agreement specifically providing for a doctor-patient relationship.***
Terms of UsePrivacy Policy
Joseph J. Timmes, Jr., M.D. • 3301 Woodburn Road Suite 204 • Annandale, VA • 22003
Tel: (703) 560-7797 • Fax: (703) 560-7897
Copyright © 2018 • Log in